Posts by ross
ODYSSEY nHCM (aka Hypertrophic Cardiomyopathy without obstruction)
We are looking for HCM patients without obstruction experiencing shortness of breath, palpitations, tiring easily, and want to be in a clinical trial. In this trial, HCM non-obstructed patients will have the opportunity to participate in a myosin inhibitor trial, which assesses the safety and efficacy of mavacamten in this population. Mavacamten is an investigational…
Read MoreFall Conferences
The Hypertrophic Cardiomyopathy Association played a key role at this fall’s HFSA and AHA conferences, actively engaging as exhibitors and offering valuable educational opportunities for the medical community. Their presence emphasized a dedication to increasing awareness and fostering discussions on hypertrophic cardiomyopathy, contributing to the broader conversation on cardiovascular health. Through their participation, the association…
Read MoreHCMA Project Opportunities
September brings many opportunities for our community to learn and share our experiences with HCM through trials, focus groups, and survey work. You have heard us stress the importance of understanding your presentation of HCM and if you are obstructed or non-obstructed. This is the prime factor in two of our projects. We are also building focus…
Read MoreHCMA travels to policy conference
Last week, I had the privilege to moderate a panel, “Novel Nursing: Helping Patients Adapt to Medical Innovation,” on the challenges and opportunities created by Myosin Inhibitors in Hypertrophic Cardiomyopathy at the PACH Cardiovascular Health Policy Summit in Washington DC. I was joined by Sue Philpott, RN, BSN – Corewell Health in Grand Rapids, MI, and Amy Beatty…
Read MoreNYHA Class Categories
Doctors usually classify patients’ heart failure according to the severity of their symptoms. The table below describes the most commonly used classification system, the New York Heart Association (NYHA) Functional Classification1. It places patients in one of four categories based on how much they are limited during physical activity. In the HCM community, this NYHA…
Read MoreACC: ORIGINAL INVESTIGATIONS Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy
BACKGROUND Septal reduction therapy (SRT), surgical myectomy, or alcohol ablation, is recommended for obstructive hypertrophic cardiomyopathy (oHCM) patients with intractable symptoms despite maximal medical therapy but is associated with morbidity and mortality. OBJECTIVES This study sought to determine whether the oral myosin inhibitor mavacamten enables patients to improve sufficiently to no longer meet guideline criteria…
Read MoreNational Mental Health Month
In recognition of Mental Health Month, the HCMA is working to raise awareness of trauma and the impact it can have on the physical, emotional, and mental well-being of children, families, and communities. Mental health is important at every stage of life, from childhood and adolescence through older adulthood. SAMHSA’s National Helpline, 1-800-662-HELP (4357) (also known as…
Read MoreICER Publishes Final Evidence Report and Policy Recommendations on Mavacamten for Hypertrophic Cardiomyopathy
ICER has released its evidence report and recommendations. Here is a list of highlights: All stakeholders have a responsibility to facilitate meaningful patient access to multidisciplinary centers of excellence for HCM in ways that do not exacerbate disparities. The manufacturer of mavacamten should commit to sponsoring research that will address the lack of evidence on…
Read More